In Switzerland
Glenmark Pharmaceuticals announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland.This manufacturing facility supplements Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development.
Powered by Capital Market - Live News
